In what was seen as a major breakthrough for the Piramal Group of Companies, the Piramal Life Sciences, a part of the group got an approval from the Regulatory Authority to commence with its Phase I activity on a new cancer molecule P-1446A-05 in Canada.

The new cancer molecule is an orally active compound which is developed in order to treat advanced cancer. It is a CDK-4 inhibitor and has higher oral bioavailability. The drug provides an edge over others as it can be given orally to the patient thus reducing hospital costs.

The Drug firm Piramal Life Sciences Ltd, had submitted the Clinical Trial Application (CTA) for approval of the Drug P-1446A-05 to Health Canada (Canada`s regulatory authority) to initiate its activity as clinical trials on its experimental cancer drug in Canada.